219 related articles for article (PubMed ID: 35504889)
1. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
[TBL] [Abstract][Full Text] [Related]
2. Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis.
Jalles C; Lepelley M; Mouret S; Charles J; Leccia MT; Trabelsi S
Therapie; 2022; 77(6):649-656. PubMed ID: 35710462
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
Liu T; Gao R; Li L; Wu B; Wu F
Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature.
Pan C; Cao M; Yan C; Ou X; Zhang X; Xu W; Xu Y; Cui X
Expert Opin Drug Saf; 2023; 22(6):469-476. PubMed ID: 36794347
[TBL] [Abstract][Full Text] [Related]
9. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
13. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS).
Mytheen S; Varghese A; Joy J; Shaji A; Tom AA
Expert Opin Drug Saf; 2023; 22(10):985-994. PubMed ID: 37294921
[TBL] [Abstract][Full Text] [Related]
14. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.
Arnaud L; Mertz P; Gavand PE; Martin T; Chasset F; Tebacher-Alt M; Lambert A; Muller C; Sibilia J; Lebrun-Vignes B; Salem JE
Ann Rheum Dis; 2019 Apr; 78(4):504-508. PubMed ID: 30793701
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study.
Pijnenburg L; Salem JE; Lebrun-Vignes B; Sibilia J; Javier RM; Arnaud L
Eur J Endocrinol; 2021 Mar; 184(3):437-444. PubMed ID: 33449911
[TBL] [Abstract][Full Text] [Related]
17. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
Johnson DB; Manouchehri A; Haugh AM; Quach HT; Balko JM; Lebrun-Vignes B; Mammen A; Moslehi JJ; Salem JE
J Immunother Cancer; 2019 May; 7(1):134. PubMed ID: 31118078
[TBL] [Abstract][Full Text] [Related]
18. Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database.
Dumont A; Dolladille C; de Boysson H; Alexandre J; Nguyen A; Deshayes S; Aouba A
Autoimmun Rev; 2022 Sep; 21(9):103157. PubMed ID: 35902047
[TBL] [Abstract][Full Text] [Related]
19. A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Song TJ
Mult Scler; 2022 Nov; 28(13):2112-2123. PubMed ID: 35822296
[TBL] [Abstract][Full Text] [Related]
20. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]